Anbio Biotechnology
NNNN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NNNN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NNNN
Anbio Biotechnology (NNNN) is a developer and marketer of in vitro diagnostic (IVD) products, including tests for infectious diseases, inflammation, and chronic conditions, with a portfolio that expanded during the COVID-19 pandemic and is now transitioning toward broader diagnostic offerings.
Key risk: Regulatory approval delays
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Anbio Biotechnology (NNNN) is a developer and marketer of in vitro diagnostic (IVD) products, including tests for infectious diseases, inflammation, and chronic conditions, with a portfolio that expanded during the COVID-19 pandemic and is now transitioning toward broader diagnostic offerings.
- Generated revenue of $8.65 million for the year ended December 31, 2025, up from $8.19 million in 2024 [sec · filed 2026-04-07].
- Gross profit improved to $7.54 million in 2025 from $5.89 million in 2024, reflecting a higher margin product mix [sec · filed 2026-04-07].
- Net income for 2025 was $6.4 million, compared to $2.37 million in 2024 [sec · filed 2026-04-07].
- Cash and cash equivalents stood at $7.77 million as of December 31, 2025, with working capital of $30.16 million [sec · filed 2026-04-07].
- Revenue from respiratory disease and COVID-19 related products declined to 20% of total revenue in 2025, down from 54% in 2024, as the company shifts focus to non-COVID IVD products [sec · filed 2026-04-07].
What works
- Revenue has grown steadily from $6.71 million in 2023 to $8.65 million in 2025, driven by increased sales of conventional IVD, animal-related, and customized products [sec · filed 2026-04-07].
- Gross profit margin improved significantly, with gross profit rising from $3.36 million in 2023 to $7.54 million in 2025, indicating better cost management or product mix [sec · filed 2026-04-07].
- The company has a diverse IVD product portfolio covering multiple disease areas and holds CE Mark certification, enabling sales in the EU and other global markets [sec · filed 2026-04-07].
- Management has experience in the diagnostic space and is pursuing strategic expansion into dry chemistry and advanced therapeutic areas to reduce reliance on pandemic-driven demand [sec · filed 2026-04-07].
What to weigh
- Revenue remains relatively modest at $8.65 million, and the company faces risks from regulatory delays and the need for additional approvals in new markets [sec · filed 2026-04-07].
- The transition away from COVID-19 products introduces execution risk, as new product lines require market acceptance, validation studies, and scaling of manufacturing [sec · filed 2026-04-07].
- The company has an accumulated deficit and relies on cash flow from operations; any significant disruption could impact liquidity [sec · filed 2026-04-07].
- Commercial success depends on maintaining supplier relationships, achieving regulatory clearances, and gaining acceptance from healthcare providers, all of which are outside the company's full control [sec · filed 2026-04-07].
From the filings
Quoted directly from source documents.
Revenue growth and reduced COVID-19 dependence
“Demand for COVID-19-related products continued to normalize; however, increased sales of conventional IVD, animal-related, and customized products supported stable overall revenue and reduced reliance on COVID-19 products.”
SEC filings · April 7, 2026
Gross profit improvement
“Our gross profit for the year ended December 31, 2025, 2024 and 2023 was approximately $7.54 million, $5.89 million and $3.36 million.”
SEC filings · April 7, 2026
Cash position and working capital
“As of December 31, 2025, we had a working capital of $30,155,023 consisting of cash and cash equivalent of $7,766,738.”
SEC filings · April 7, 2026
Regulatory and commercialization risks
“Our strategic transition involves risks and uncertainties, as expansion into new sectors may require additional regulatory approvals, validation studies, and commercialization efforts, which could result in delays or increased costs.”
SEC filings · April 7, 2026
Risks & what to watch (4)›
Key risks
- Regulatory approval delays — Expansion into new sectors may require additional regulatory approvals, validation studies, and commercialization efforts, causing delays or increased costs [sec · filed 2026-04-07].
- Market acceptance of new products — Success of dry chemistry and new offerings depends on market acceptance, competitive positioning, and ability to scale manufacturing and distribution [sec · filed 2026-04-07].
- Dependence on key customers and suppliers — Business depends on maintaining relationships with suppliers and customers; failure could materially affect operations and financial condition [sec · filed 2026-04-07].
- IVDR compliance deadlines — Failure to secure IVDR compliance for CE-marked products by deadlines could affect EU sales, which represented a portion of revenue [sec · filed 2026-04-07].
What to watch
- Progress of regulatory submissions for IVD products in new regional markets, which could impact revenue growth [sec · filed 2026-04-07].
- Adoption and sales trajectory of the dry chemistry product line and other new diagnostic offerings [sec · filed 2026-04-07].
- Ability to maintain or improve gross profit margins as the product mix shifts away from COVID-19 tests [sec · filed 2026-04-07].
- Cash flow generation and working capital management, given the modest cash position of $7.77 million [sec · filed 2026-04-07].
Sources: SEC filings · Generated August 11, 2026 · How we verify sources →
Run Anbio Biotechnology through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Anbio Biotechnology facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
7.7 months
D/E 0.00 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
5
Total value held
$1.4M
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 25,763 | $662K |
| eversource wealth advisors, llc | 1,696 | $317K |
| bnp paribas financial markets | 10,400 | $267K |
| morgan stanley | 7,338 | $189K |
| wells fargo & company/mn | 100 | $3K |
Short Interest
as of Apr 30, 2026- % of float
- 0.1%
- Days to cover
- 1.9
- Shares short
- 52,247
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NNNN short interestFrequently asked questions
What is the AI investment thesis for Anbio Biotechnology?
Anbio Biotechnology (NNNN) is a developer and marketer of in vitro diagnostic (IVD) products, including tests for infectious diseases, inflammation, and chronic conditions, with a portfolio that expanded during the COVID-19 pandemic and is now transitioning toward broader diagnostic offerings.
Who is the CEO of Anbio Biotechnology?
Mr. Michael Lau M.B.A., Ph.D. is the chief executive officer of Anbio Biotechnology (NNNN).
Where is Anbio Biotechnology headquartered?
Anbio Biotechnology (NNNN) is headquartered in Frankfurt am Main, Germany.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.